Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line

NCT05312398 is registered in ClinicalTrials.gov with University of Campania Luigi Vanvitelli as lead sponsor.

NCT NCT05312398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line
Lead sponsor
University of Campania Luigi Vanvitelli
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 15, 2021
Completion date
August 15, 2026
Enrollment
219 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal adenocarcinoma